• PRITHIVIRAJ NAGARAJAN Multi-Disciplinary Centre for Biomedical Research, Aarupadai Veedu Medical College & Hospital, Vinayaka Mission’s Research Foundation (Deemed to be a University), Puducherry-607 403, India.
  • JAYANTHI KUMAR Directorate of Indian System of Medicine and Homeopathy, Government of Puducherry, Puducherry, India.
  • ANUSHEELA HOWLADER Department of Microbiology, Aarupadai Veedu Medical College & Hospital, Vinayaka Mission’s Research Foundation (Deemed to be University), Puducherry-607 403, India.
  • SATHEESH KUMAR SABAPATHY SRL limited, Department of Molecular Biology, New Avadi Road, Kilpauk, Sreerosh Renaissance, Chennai, Tamil Nadu, India.
  • MUTHU GOPAL Model Rural Health Research, Primary Health Centre, Tirunelveli, Tamil Nadu, India.
  • LEENA RAJATHY PORT LOUIS Department of Pharmacology, Aarupadai Veedu Medical College & Hospital, Vinayaka Mission’s Research Foundation (Deemed to be University), Puducherry-607 403, India.
  • SARAVANAAVEL KUMAR Department of Microbiology, Aarupadai Veedu Medical College & Hospital, Vinayaka Mission’s Research Foundation (Deemed to be a University), Puducherry-607 403, India.



Omicron, Severe acute respiratory syndrome coronavirus type 2, Prevalence, Outbreak, Clinical characteristics


Early 2022 saw an outbreak of the coronavirus severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variant known as Omicron, which has become more contagious than the previous variants of concern alpha, beta, and gamma variants, and it shares many mutations. Still, so far, Omicron transmission has exceeded many borders worldwide compared to other kinds of SARS-CoV-2; there has been a significant increase in the number of confirmed cases globally, and it is re-emerging currently in India. The World Health Organization, the Centers for Disease Control and Prevention (CDC), the Ministry of Health and Family Welfare, and other research institutions, as well as worldwide international press media provided data on “Omicron” outbreaks in India. Our review recorded information about the prevalence and clinical characteristics of the Omicron variant of SARS-CoV-2 from November 24, 2021, to January 17, 2022. Our highlights will talk about its global transmission, characteristics, and impact on vaccine efficiency, and possible strategies to prevent and overcome the spread of the Omicron variant.


Download data is not yet available.


World Health Organization. Coronavirus Disease (COVID-19). Geneva: World Health Organization; 2019. Available from: https:// [Last accessed on 2020 Oct 03].

Tracking SARS-CoV-2 Variants. Available from: https://www.who. int/activities/tracking-SARS-CoV-2-variants [Last accessed on 2022 Apr 29].

World Health Organization. Omicron may already be in Most Countries, WHO Warns. Available from: health/omicron-may-already-be-in-most-countries-who-warns-80704 [Last accessed on 2022 Apr 29].

Chappell B. Omicron Spreads Faster than any other Variant, WHO Says. It’s now in 77 Countries. Washington, DC, United States: National Public Radio; 2021.

COVID: First UK Death Recorded With Omicron Variant BBC News. Available from: [Last accessed on 2022 Apr 29].

Kannan S, Ali PS, Sheeza A. Evolving biothreat of variant SARS-CoV-2 molecular properties, virulence and epidemiology. Eur Rev Med Pharmacol Sci 2021;25:4405-12. Available from:

Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, et al. Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. Am J Pathol 2016;186:652-58.

Barlan A, Zhao J, Sarkar MK, Li K, McCray BP Jr., Perlman S, et al. Receptor variation and susceptibility to middle east respiratory syndrome coronavirus infection. J Virol 2014;88:4953-61. https://doi. org/10.1128/JVI.00161-14

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Pediatr Med Rodz 2020;16:9-26. https://doi. org/10.15557/PiMR.2020.0003

Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et al. Severe neurologic syndrome associated with middle east respiratory syndrome corona virus (MERS-CoV). Infection 2015;43:495-501.

Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 omicron variant. J Med Virol 2022;94:2376-83.

Thakur V, Ratho RK. OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol 2022;94:1821-4.

Tan Z, Chen Z, Yu A, Li X, Feng Y, Zhao X, et al. The first two imported cases of SARS-CoV-2 omicron variant Tianjin Municipality, China, December 13, 2021. China CDC Wkly 2022;4:76-7. https://doi. org/10.46234/ccdcw2021.266

Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1-23. https://doi. org/10.1007/978-1-4939-2438-7_1

Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill 2021;26:2002106. ES.2020.26.1.2002106

Zuckerman NS, Fleishon S, Bucris E, Bar-Ilan D, Linial M, Bar-Or I, et al. A unique SARS-CoV-2 spike protein P681H variant detected in Israel. Vaccines (Basel) 2021;9:616. vaccines9060616

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020;2020:914952.

Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-9.

de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523-34.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74. https://doi. org/10.1016/S0140-6736(20)30251-8

Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181-92. 018-0118-9

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.e8.

Chowell G, Abdirizak F, Lee S, Lee J, Jung E, Nishiura H, et al. Transmission characteristics of MERS and SARS in the healthcare setting: A comparative study. BMC Med 2015;13:210. https://doi. org/10.1186/s12916-015-0450-0

Raj VS, Osterhaus AD, Fouchier RA, Haagmans BL. MERS: Emergence of a novel human coronavirus. Curr Opin Virol 2014;5:58- 62.

Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): A study of 63 patients in Wuhan, China. Eur Radiol 2020;30:3306-9.

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav 2021;5:947-53.

Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo- Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill 2021;26:2100438. https://doi. org/10.2807/1560-7917.ES.2021.26.21.2100438

Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Guevara M, Fernández-Huerta M, Burgui C, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill 2021;26:2100894.

Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission. medRxiv 2021;2021:21264260.

Meyer ED, Sandfort M, Bender J, Matysiak-Klose D, Dörre A, Bojara G, et al. Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary attack rate: Evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, January- March 2021. medRxiv 2021;2021:21262519.

Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. Epidemiology 2021;27:2136-43.

Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021;27:2127-35.

Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. N Engl J Med 2021;385:e90. https://doi. org/10.1056/NEJMoa2106599

Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine effectiveness and duration of protection of comirnaty, vaxzevria and spikevax against mild and severe COVID-19 in the UK. 2021;2021:21263583.

Hitchings MD, Ranzani OT, Dorion M, D’Agostini TL, de Paula RC, de Paula OF, et al. Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo. Nat Commun 2021;12:6220.

Ranzani OT, dos Santos Leite R, Castilho LD, Gonçalves CC, Resende G, de Melo RL, et al. Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: A test-negative study design. 2021;2021.10.15.21265006

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available from: classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern [Last accessed on 2022 Apr 29].

Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 2021;4:e2140364. https://doi. org/10.1001/jamanetworkopen.2021.40364

Burki TK. Omicron variant and booster COVID-19 vaccines. Lancet Respir Med 2022;10:e17. 2600(21)00559-2

Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: Experts’ consensus statement. World J Pediatr 2020;16:223-31.

Pulliam JR, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa. Science 2022;376:eabn4947.

Mahase E. Covid-19: UK approves monoclonal antibody sotrovimab for over 12s at high risk. BMJ 2021;375:n2990. bmj.n2990

Cheng SM, Mok CK, Leung YW, Ng SS, Chan KC, Ko FW, et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med 2022;28:486-9. 022-01704-7

Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv 2021;2021:21267417. https://doi. org/10.1101/2021.12.08.21267417

Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science 2022;375:331-36.

Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA 2022;327:639-51. jama.2022.0470

Sohan MD, Hossain MD, Islam MD. The SARS-CoV-2 omicron (B.1.1.529) variant and effectiveness of existing vaccines: What we know so far. J Med Virol 2022;94:1796-8. jmv.27574

Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv 2021;2021:21267432.

Choi A, Koch M, Wu K, Chu L, Ma LZ, Hill A, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: An interim analysis. Nat Med 2021;27:2025-31. https://

News GP. How Vaccine Companies are Responding to Omicron. News GP. Available form: how-vaccine-companies-are-responding-to-omicron [Last accessed on 2022 Apr 29].

Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.

Thiagarajan K. What do we know about India’s covaxin vaccine? BMJ 2021;373:n997.

Momin T, Kansagra K, Patel H, Sharmaa S, Sharmaa B, Patel J, et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. eClinicalMedicine 2021;38:101020. eclinm.2021.101020

Baraniuk C. Covid-19: What do we know about Sputnik V and other Russian vaccines? BMJ 2021;372:n743.

Lingadurai S, Mariappan G. Adverse events following immunization (AEFI) for Covid vaccines approved by WHO a short review. IP Int J Compr Adv Pharmacol 2022;7:40-3.

Nakkala K, Godiyal S, Laddha KS. Isolation of starch from Curcuma longa L. and its characterization. Int J Pharm Sci Res 2020;11:5712-7.

Macha B, Nakkala K, Garige A, Akkinepally RR, Garlapati A. Synthesis and evalution of new tacrine derivatives as anti-Alzheimer’s agents. Int J Pharma Bio Sci 2018;8:590-7.



How to Cite

NAGARAJAN, P., J. KUMAR, A. HOWLADER, S. K. SABAPATHY, M. GOPAL, L. R. PORT LOUIS, and S. KUMAR. “SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS TYPE 2 OMICRON VARIANT OUTBREAK IN INDIA: TIME TO ALERT”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 6, June 2022, pp. 1-8, doi:10.22159/ajpcr.2022.v15i6.44731.



Review Article(s)